Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (currently amended): A trimeric polypeptide comprising three monomers, wherein each of said-monomer[[s]] comprising comprises a specific cytokine binding member capable of binding a trimeric cytokine domain[[,]] and each of said-monomers comprising a tetranectin trimerising domain, the trimerising domain is derived from tetranectin.

Claims 2-17 (cancelled).

Claim 18 (currently amended): The A-trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain-derived from tetranectin comprises an amino acid sequence having at least 68% amino acid sequence 87% identity with the amino acid sequence of SEQ ID NO:81.

Claim 19 (currently amended): <u>The A-trimeric polypeptide according to claim-18_1</u>, wherein the <u>tetranectin trimerising domain comprises an amino acid sequence identity is having</u> at least 92% identity with the amino acid sequence of SEO ID NO:81.

Claim 20 (currently amended): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain derived from tetranectin comprises the amino acid sequence of SEQ ID NO:81.

Claim 21 (currently amended): The trimeric polypeptide according to claim 1, wherein the at least one monomer comprises the amino acid sequence of is-TN-2-B (SEQ ID NO:106), TN-2-C-(_SEQ ID NO:108), or-TN-2-D-(_or_SEQ ID NO:107[D]].

Claim 22 (currently amended): The trimeric polypeptide according to claim 1, further comprising a linker between the speeifie-cytokine binding member-domain and the tetranectin trimerising domain.

Claim 23 (previously presented): A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.

Claims 24-29 (cancelled).

Claim 30 (previously presented): A method of preparing a pharmaceutical composition comprising combining the trimeric polypeptide according to claim 1 with a pharmaceutically acceptable carrier.

Claims 31-34 (cancelled).

Claim 35 (currently amended): The trimeric polypeptide according to claim 20, wherein the cysteine residue at position number 50 of the amino acid sequence of SEQ ID NO:81 is mutagenized to a serine, threonine, methionine, or any other amino acid residue.